Tiriz

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tiriz

Quick Facts

Property Description
Active ingredient Levocetirizine dihydrochloride
Form Film-coated tablets, Oral solution, Drops
Pharmacological class Second-generation Antihistamine
Common purpose Symptomatic relief of allergy
Origin Synthetic compound

What Type of Medicine is Tiriz?

Tiriz is an oral pharmaceutical preparation classified as a second-generation antihistamine, primarily used for the symptomatic relief of allergy and hypersensitivity reactions. The medication's active ingredient, Levocetirizine dihydrochloride, belongs to the pharmacological class of Histamine H1-receptor antagonists. This classification places it among modern anti-allergy agents designed to manage physical allergic discomforts with a lower tendency for sedative effects compared to older (first-generation) compounds. The medication is used to alleviate seasonal allergic rhinitis symptoms. This clinically recognized efficacy means the medicine helps to ease the common nasal and ocular discomfort associated with allergies, a typical use scenario.


Composition and Form: Understanding Levocetirizine

The sole active ingredient in Tiriz is Levocetirizine dihydrochloride. Chemically, this compound is a synthetic compound derived as the pure, active R-enantiomer of the substance Cetirizine. This specific enantiomer is responsible for the majority of the pharmacological activity. Tiriz is prepared for oral administration and is available in multiple dosage forms, including film-coated tablets, an oral solution, and drops. A differentiating factor is the availability of liquid forms, which are specifically positioned to ensure easy, systemic use for paediatric patients or adults who may have difficulty swallowing tablets.


How Tiriz Works at a High Level

Tiriz's function is executed through its primary action as a selective peripheral H1-receptor antagonist. This involves the active ingredient, Levocetirizine, binding to and blocking the H1-receptors that are located on cells outside the central nervous system. By occupying these receptor sites, the drug achieves its essential anti-allergic action by preventing the natural chemical histamine, released during a hypersensitivity reaction, from triggering common symptoms. This selective peripheral blockade is the mechanism that translates directly into the general benefit of mitigating allergic signs at their root cause.

Regulatory References

  1. MedlinePlus Drug Information
  2. PubMed
  3. NIH LiverTox

What side effects are possible with Tiriz?

Possible Side Effects and Safety Information

The safety profile of Tiriz (Levocetirizine) is categorized by regulatory bodies based on the frequency and type of adverse reactions reported in clinical data and post-marketing surveillance.

Adverse Reaction Classifications

The officially listed effects are typically classified by frequency and System-Organ Class (SOC):

Classification Example Adverse Reactions
Common (Affecting 1 in 100 to 1 in 10) Somnolence, Fatigue, Dry mouth, Nasopharyngitis, Pharyngitis.
Uncommon (Affecting 1 in 1,000 to 1 in 100) Asthenia (weakness), Abdominal pain.

Adverse reactions have been reported across several SOCs, including Nervous System Disorders (e.g., somnolence, headache) and Gastrointestinal Disorders (e.g., dry mouth, diarrhea). Rare adverse reactions (affecting less than 1 in 1,000) documented in regulatory sources include Tachycardia (rapid heart rate) and Hypersensitivity reactions.

Serious Reactions and Safety Constraints

Post-marketing reports document serious adverse reactions such as Anaphylaxis (severe allergic reaction), Convulsions, and Hepatic function abnormalities.

Safety constraints and limitations are explicitly defined for specific populations. The medicine is contraindicated in individuals with End-Stage Renal Disease (very severe kidney impairment). Caution is also officially advised for older adults and patients with conditions predisposing to urinary retention, due to an increased potential for adverse effects in these groups. Additionally, a time-related safety pattern has been documented: cases of severe pruritus (itching) have been reported upon the cessation of long-term daily use of Levocetirizine.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented overdose information for Tiriz, strictly based on authoritative government regulatory sources. It is not intended as medical advice but as a summary of the official product labeling regarding acute toxicity.


Documented Overdose Profile

Official regulatory documents indicate that an overdose of Tiriz may result in an exaggeration of known pharmacological effects, potentially leading to severe central nervous system (CNS) depression and cardiovascular instability, including hypotension and rhythm disturbances. The severity of the manifestation is often dose-dependent.

Population-specific considerations documented in the labeling suggest that pediatric and geriatric patients, as well as those with hepatic or renal impairment, may be at higher risk for severe or prolonged toxicity.

Required Emergency Actions

Immediate medical help is required in all cases of known or suspected Tiriz overdose, regardless of whether symptoms are present. This instruction is explicitly mandated by regulatory authorities.

In a clinical setting, management is primarily supportive and symptomatic. Official protocols emphasize maintaining a patent airway and providing adequate ventilation. Continuous monitoring of cardiac function and vital signs is specified as a necessary measure. While treatment is tailored to the patient’s clinical condition, the regulatory labeling provides guidance on potential supportive measures, such as the use of activated charcoal and fluid resuscitation, and indicates whether the substance is dialyzable.

Therapeutic Uses of Tiriz

What Tiriz Treats: Main Uses and Benefits

Tiriz is commonly used to relieve symptoms caused by allergies, focusing on two major domains. It is applied across conditions characterized by episodic or fluctuating symptom patterns, particularly for seasonal and perennial allergic rhinitis, allergic conjunctivitis, and chronic idiopathic urticaria.

Upper Airway and Skin Symptom Relief

This medication is generally considered relevant for easing symptoms that interfere with daily comfort, such as persistent sneezing, watery eyes (lacrimation), excessive runny nose (rhinorrhea), and intense skin itching (pruritus). It is often used during phases when symptoms become more noticeable, offering symptomatic relief that helps patients cope more steadily with difficult episodes.

“This approach assists with maintaining functional stability and supports patients during episodes of heightened discomfort.”

In clinical settings involving increased physiological stress from allergies, this supportive relief helps ease the overall symptom burden.


Quick Fact: Relief for Itching and Nasal Symptoms Use Case Therapeutic Benefit
Allergic Rhinitis Eases persistent sneezing and nasal congestion.
Chronic Urticaria Supports the easing of generalized skin itching.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Tiriz — Official Regulatory Information

Tiriz (cetirizine) is an antihistamine for use in adults and children, but official regulatory documents strictly define populations who can and cannot take the medicine, primarily based on contraindications, age, and clinical state.


Eligibility Scope

Classification Populations Covered Eligibility Status
Allowed Use Adults and adolescents 12 years and older; Children 6 years and older (tablets); Children 6 months and older (oral/IV solution, dependent on indication and formulation). Allowed/Established Use
Contraindicated Patients with known hypersensitivity to the active substance, to any excipients, to hydroxyzine, or to any piperazine derivatives; Patients with severe renal impairment (creatinine clearance <10 mL/ min). Prohibited
Restricted/Not Recommended Children under 6 years of age (for most tablet formulations); Patients with moderate renal impairment or hepatic impairment; Women who are breastfeeding. Use Caution/Ask a Doctor

Eligibility-Related Restrictions

  • Condition-Specific Rules: A dose adjustment is required for patients with moderate kidney or liver disease. The medicine is generally not recommended for children under 6 years of age who have impaired renal or hepatic function.
  • Physiological States: Use is not recommended for women who are breastfeeding as the substance is present in breast milk. Pregnant women should ask a health professional before use.
  • Cautionary Groups: Patients with a predisposition for urinary retention or who are epileptic or at risk of convulsions should use the medicine with caution. Certain tablet forms are also prohibited in patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

In summary, regulatory documents establish use based on age, while strictly prohibiting use in cases of severe kidney failure and allergic reactions to the drug or related compounds. Other groups require a doctor's consultation or dose adjustment.

What should I know about interactions with other medicines?

Tiriz Interactions with other medicines and products

Official regulatory information regarding interactions with Levocetirizine is categorized by the nature of the constraint, covering pharmacodynamic effects, exposure modification, and specific population restrictions.

Pharmacodynamic Restrictions

Concurrent use with certain substances can lead to additive effects on the central nervous system (CNS). Alcohol and other CNS depressants should be avoided, as co-administration may cause additional impairment of performance and a reduction in alertness.

Exposure-Altering Drug Interactions

The official regulatory profile documents specific interactions resulting in altered systemic exposure. Co-administration of the parent compound (cetirizine) with Ritonavir led to an approximate 42% increase in total systemic exposure and a reduction in clearance. Co-administration with Theophylline also resulted in a small decrease in the clearance of the parent compound. However, official studies demonstrated no clinically relevant adverse interactions with medicines such as Antipyrine, Azithromycin, Cimetidine, Erythromycin, Ketoconazole, or Pseudoephedrine.

Interactions with Food

Taking this medicine with food does not reduce the overall amount of the drug absorbed into the body. However, the rate of absorption is decreased, resulting in a delay in reaching the maximum blood concentration.

Population-Based Restrictions

Use is formally contraindicated in patients with End-Stage Renal Disease, defined as a creatinine clearance less than 10 mL/min. This restriction also applies to pediatric patients with impaired kidney function. This constraint is mandated because the drug is substantially excreted by the kidneys, increasing the risk of accumulation due to reduced clearance.

Mechanism of Action

The mechanism of action of the active ingredient, Levocetirizine, is defined by its targeted action on two complementary mechanistic domains: H1-receptor blockade and influencing inflammatory cell activity.


H1-Receptor Blockade with Peripheral Selectivity

This domain covers the primary molecular interaction of the molecule, which involves binding with high affinity to the Histamine H1-receptor (H1R) found outside the central nervous system. By acting as an antagonist, the molecule prevents the natural chemical histamine from activating these receptors, thereby preventing the immediate signaling cascade that results in increased vascular permeability (fluid leakage) and sensory nerve excitation.


Modulation of Inflammatory Cell Pathways

The mechanism extends beyond receptor blockade to influence the wider biological response. The molecule exerts a secondary effect by restricting the recruitment and function of key immune cells, specifically the chemotaxis and adhesion of eosinophils to sites of activity. This domain influences pathways associated with heightened physiological responses, which biologically restricts the progression of cellular inflammation by limiting the activity of key cells.

Dosage and Administration Information

Administration and Dosing Guidelines for Tiriz

Tiriz (cetirizine) is administered either orally (as a tablet, capsule, or solution) or via intravenous (IV) injection by a healthcare professional. The prescribed dosage and frequency should be followed exactly as directed by a healthcare provider or according to the product labeling, typically once every 24 hours (daily). Oral forms can be taken with or without food.

Official Dosing Rules

The recommended dose varies based on age and route of administration:

  • Adults and Adolescents (12 years and older): The standard oral dose is 10 mg once daily; a 5 mg dose may be appropriate for less severe symptoms. The IV dose is 10 mg. The maximum oral dose is 10 mg per 24 hours.
  • Children (6 to 11 years): The standard oral dose is 5 mg or 10 mg once daily. The IV dose is 5 mg or 10 mg, depending on symptom severity.
  • Children (6 months to 5 years): The IV dose is 2.5 mg once every 24 hours. The oral solution initial dose is typically 2.5 mg once daily, not to exceed 5 mg per day.

Preparation and Special Conditions

Administration Aspect Official Instruction
Oral Tablet/Capsule Swallow whole with liquid; do not chew standard forms.
Oral Solution/Syrup Use a calibrated measuring device (syringe or spoon); do not use a household teaspoon.
IV Injection Administer as an intravenous push over a period of 1 to 2 minutes.
Renal/Hepatic Impairment Oral dose reduction is required in patients aged 12 years and older with moderate to severe renal impairment (e.g., 5 mg daily); consult a healthcare professional for adjustment. No IV dose adjustment is generally required for short-term use.

Missed Dose Instructions

If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule should be resumed. Do not take a double dose to make up for a missed dose.

Recent Clinical Evidence

Tiriz: Recent Clinical Evidence

Clinical research on Tiriz primarily involves its use as a treatment for Type 2 Diabetes Mellitus (T2DM). The evidence base includes multiple Phase 3 trials and long-term extension studies, generally comparing Tiriz against placebo or other standard-of-care agents.


Key Findings on Glycemic Control

Major randomized controlled trials (RCTs) suggest that Tiriz, when used alone or added to existing therapy, was associated with a reduction in two primary markers of blood sugar control: Hemoglobin A1c (HbA1c) and Fasting Plasma Glucose (FPG). These changes were reported to be statistically significant in the studied populations compared to placebo.

  • HbA1c Reduction: Across several 26- to 52-week trials, the mean reduction in HbA1c observed with Tiriz was within the range of 1.5% to 2.5% from baseline, depending on the dose and the specific patient population studied.
  • Target Achievement: A higher proportion of study participants receiving Tiriz reached the goal of an HbA1c of less than 7.0% compared to participants receiving placebo or certain other diabetes medications.

Cardiovascular and Weight Outcomes

While Tiriz is indicated for T2DM, studies have also provided data regarding certain non-glycemic factors:

  • Body Weight: Trials consistently observed that treatment with Tiriz was associated with a reduction in body weight in individuals with T2DM. The weight loss was generally dose-dependent and sustained over the duration of the trials.
  • Cardiovascular Safety: Dedicated studies were conducted to assess the overall cardiovascular safety profile of Tiriz. The findings did not indicate an increased risk of major adverse cardiovascular events (MACE) in participants taking Tiriz when compared to placebo or other common diabetes treatments in the study setting.

It is important to understand that the evidence reflects outcomes observed in specific, structured research settings, and individual results may vary.

Key Studies & References

  1. Tirzepatide Once Weekly for the Treatment of Type 2 Diabetes (Overview of SURPASS Trials)
  2. The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials

Frequently Asked Questions (FAQ)

Common questions about Tiriz (FAQ)

Q: What is the main condition Tiriz is officially used to treat?

A: Regulatory documents indicate that Tiriz is officially approved for the relief of symptoms associated with seasonal and perennial allergic rhinitis, which includes outdoor and indoor allergies. It is also indicated for the treatment of uncomplicated skin conditions like chronic idiopathic urticaria, commonly known as chronic hives.

Q: Is Tiriz the same kind of medicine as other common allergy relief products?

A: Tiriz belongs to the class of second-generation antihistamines. Official product information describes it as the active component (R-enantiomer) of the related drug cetirizine. Antihistamines are generally medicines used to reduce the effects of histamine in the body.

Q: How quickly can a person expect Tiriz to start working after they take it?

A: Studies on the medicine have examined the onset of action after an oral dose. Evidence indicates that symptom relief may begin to be experienced as early as 1 hour after taking the medicine.

Q: Is Tiriz intended for short-term use for allergy flares or for daily, long-term conditions?

A: Official labeling states the medicine is approved for both short-term and long-term use. This covers short periods for seasonal allergic flare-ups as well as daily, long-term management of chronic conditions like perennial allergic rhinitis or chronic hives.

Q: Does Tiriz stay in the body for 24 hours?

A: The medicine is generally prescribed to be taken once daily. While the amount of time the drug remains in the plasma (half-life) is approximately 8 to 9 hours in adults, official studies show it provides a significant antihistaminic effect for a full 24 hours after a single dose.

Q: What is the difference between the brand name and generic versions of Tiriz?

A: The generic version contains the exact same active ingredient, levocetirizine dihydrochloride, as the brand name product. Regulatory agencies require that all generic versions demonstrate bioequivalence, meaning they work in the body the same way and at the same rate as the original branded drug.

Q: Why might a person feel dizzy or lightheaded while taking Tiriz?

A: Official warnings note that this medicine may cause central nervous system effects such as drowsiness (somnolence) and fatigue. Feelings of dizziness or lightheadedness may accompany these common effects. Caution is noted until a person knows how the medicine affects them.

Q: Are there any long-term health effects noted in studies for people who use Tiriz daily for years?

A: Studies generally focus on short- to medium-term data. However, regulatory documents have noted that cases of severe itching (pruritus) have been reported upon stopping the medicine after long-term, daily use. This is included in the official safety information.

Q: What types of over-the-counter (OTC) pain relievers or cold medicines interact with Tiriz?

A: The official label notes that concurrent use of this medicine with other Central Nervous System (CNS) depressants, including alcohol, sedatives, and tranquilizers, is advised to be avoided due to the potential for increased drowsiness or impairment.

Q: Are there any specific foods or drinks that should be avoided when taking Tiriz?

A: Official safety warnings advise that the concurrent use of alcohol with this medication should be avoided. Combining the two can cause an additional reduction in alertness and increase the risk of drowsiness and impairment.

Q: Can Tiriz be used by older adults (e.g., those over 65)?

A: Official guidance advises using the drug with caution in older adults. Dosage adjustments may be required, particularly in those with reduced kidney function, as the medicine is primarily cleared by the kidneys.

Q: Can children of all ages use Tiriz, or are there age restrictions?

A: The medicine is formally indicated for use in children as young as 6 months for certain chronic allergic conditions, such as perennial allergic rhinitis. Dosing is based on age and body weight, and is intended to be used only as directed by a healthcare professional.

Q: If a person has a history of kidney or liver issues, can they still use Tiriz?

A: Use is formally contraindicated (not recommended) for patients with very severe kidney impairment, specifically End-Stage Renal Disease, as stated in the product labeling. For less severe kidney issues, a dose reduction may be recommended. No dose adjustment is generally required for liver impairment alone.

Q: Is Tiriz considered safe to use during pregnancy based on available research?

A: The official regulatory guidance states that individuals who are pregnant or planning to become pregnant are advised to consult a healthcare professional before using the drug. This is a standard caution provided when specific human data is limited.

Q: Does the medicine pass into breast milk, and what is the official guidance on using Tiriz while breastfeeding?

A: Official product information on this drug states that the medicine is not generally recommended for use while breastfeeding. This topic requires consultation with a healthcare provider to review the risks and benefits.

Q: What is the difference in how Tiriz works compared to older generation allergy medicines?

A: This medicine is a newer, second-generation antihistamine. Its primary action involves selectively blocking the H1-receptor. The official mechanism of action also notes a secondary effect on the movement of inflammatory cells (eosinophils) to reduce the overall allergic response.

Q: Does Tiriz work by blocking histamine, and what does that mean in simple terms?

A: Yes, it works by acting on the Histamine H1-receptor. In simple terms, this means it prevents the natural chemical histamine, which is released during an allergic reaction, from causing immediate symptoms like itching and fluid leakage.

Q: Are there different forms of Tiriz available, such as tablets, liquids, or chewables?

A: The medicine is available as an oral tablet and an oral solution (liquid). The oral solution form is often used as an alternative for people who have difficulty swallowing tablets.

Q: Is Tiriz available to purchase without a prescription?

A: Official regulatory documents indicate that the oral forms of this medicine are available for purchase without a prescription (Over-the-Counter or OTC).

Q: Does taking Tiriz at different times of the day affect how well it works?

A: Official dosing instructions typically recommend taking the medicine once daily in the evening. This timing is intended to provide consistent symptom relief over the full 24-hour period.

Q: What should be done if a user notices their symptoms are not getting better after several days of using Tiriz?

A: Official patient counseling information suggests that if symptoms do not start to improve or if they worsen while using the medicine, a healthcare professional should be consulted. This ensures appropriate medical guidance is received.

Q: Can Tiriz be used to treat hives that are not typically itchy or are discolored?

A: The medicine is indicated for the treatment of uncomplicated hives (chronic idiopathic urticaria). Clinical studies specifically report its effectiveness in decreasing the severity and duration of pruritus (itching) and the number and size of wheals (hives).

Q: Is it true that taking a higher dose of Tiriz increases the chance of feeling drowsy?

A: Drowsiness is a common adverse reaction associated with the medicine. Official instructions advise against exceeding the recommended dose because higher doses may lead to increased exposure and greater risk of CNS effects, including drowsiness.

Q: Does Tiriz help with symptoms other than sneezing and a runny nose?

A: Yes. Clinical studies indicate the medicine is effective in relieving both nasal symptoms, such as sneezing, and non-nasal symptoms. This includes relief for eye-related symptoms like itching and watering associated with allergic rhinitis.

Q: What is the shelf life of Tiriz, and how should it be stored?

A: Official labeling states the medicine should be stored between 20 and 25 C (68 and 77 F). The oral solution must be used within a certain period after opening, and all forms must be kept out of the sight and reach of children.

Q: Can using Tiriz make a cough or sore throat worse?

A: Adverse reactions reported in clinical trials include nasopharyngitis and pharyngitis, which are forms of throat inflammation or sore throat symptoms. These are classified as common side effects of the medicine.

Q: Is there a different combination product (like Tiriz-D) that contains a decongestant?

A: Yes. There is an available product that combines the active ingredient of Tiriz (levocetirizine) with the decongestant pseudoephedrine, which is sometimes marketed under a combination trade name ending in '-D'.

Q: What is the maximum amount of time a person can safely take Tiriz?

A: The medicine is indicated for long-term use for chronic conditions. Official patient counseling indicates that long-term use, especially for several months or more, warrants discussion with a healthcare professional to review the benefits and risks.

Q: What happens to Tiriz after it is metabolized by the body?

A: Pharmacokinetic data shows that the majority of the medicine, approximately 85%, is excreted from the body through the urine. It is excreted by both glomerular filtration and active tubular secretion, with minimal metabolism (breakdown) in the liver.

Q: How effective is Tiriz for relieving chronic hives versus seasonal allergies?

A: Clinical studies have shown the medicine to be effective against both seasonal allergic rhinitis and chronic idiopathic urticaria (hives). It has been demonstrated to reduce symptoms in both conditions when compared to a placebo.

Q: Are there any specific safety warnings that the FDA or other regulators have issued about Tiriz?

A: Official warnings include the risk of somnolence (drowsiness), caution for conditions that may lead to urinary retention (trouble passing urine), and the risk of severe itching upon stopping the medicine after long-term use.

Q: What are the signs of a serious or rare side effect associated with Tiriz?

A: Serious side effects reported after the drug became available include severe allergic reactions (anaphylaxis), convulsions, and severe liver function abnormalities. Symptoms of a severe allergic reaction may include sudden rash, hives, swelling of the face, or trouble breathing.

Q: Can Tiriz affect a person's ability to drive or operate machinery?

A: Official warnings state that patients should exercise caution regarding engaging in hazardous activities, such as driving or operating machinery, until they are aware of the medicine's potential effects on them. This is due to the risk of drowsiness and impairment.

Q: If a person is taking other prescription medications, is an interaction check necessary before starting Tiriz?

A: Yes. Official patient counseling information indicates that a healthcare provider should be informed about all prescription and nonprescription medications, vitamins, and herbal products currently being taken, as drug interactions are possible.

Q: Can I crush or split the Tiriz tablet if I have trouble swallowing pills?

A: The standard oral tablet is generally scored (has a line), which allows for the tablet to be broken in half to administer a lower dose. The oral solution is also available as an alternative form for individuals who have trouble swallowing pills.

Q: Does Tiriz carry a warning about central nervous system depression?

A: Yes. The medicine carries a warning about somnolence (drowsiness) and a caution against concurrent use with alcohol or other central nervous system depressants. This is because combining these substances can cause additional impairment and CNS depression.

How should Tiriz be stored and disposed of?

Storage Requirements

All forms of Tiriz (levocetirizine) must be stored under specific conditions to maintain product stability, as detailed in regulatory documents.

Storage Rule Requirement
Temperature Do not store above 30 C (86 F); the product must not be frozen.
Protection Keep the medicine protected from light and ensure the oral solution bottle is kept tightly closed.
Child Safety Mandatory to keep Tiriz out of the sight and reach of children.

Stability and Disposal

The oral solution must be used within 6 months after the initial opening; any remaining product should be discarded after this period. Unused or expired medicine must not be disposed of via wastewater or household waste. Official instructions require the user to consult a pharmacist for guidance on proper disposal procedures to help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tiriz found in:

A-Z Index: